DexCom price to free cash flow DXCM

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: 20.9×
9-year median: 146×
Against its 9-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
9-year range: 16.4× to 500×
Peer median: 22.7×

DexCom's price to free cash flow is 20.9× as of Oct 23, 2026.

That is below its 9-year median of 146×, lower than on 97% of days in the last 9 years.

Over that time it ranged from 16.4× in May 2026 to 500× in Aug 2021.

The median for 9 medical device stocks of a similar size is 22.7×.

Price to free cash flow over time

median 145.7×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.9×	16.4×	26.8×
2025	24.8×	20.2×	65.0×
2024	58.6×	38.5×	105×
2023	95.9×	63.4×	171×
2022	167×	147×	424×
2021	373×	120×	500×
2020	134×	115×	433×
2019	392×	162×	409×
2018	165×	151×	366×
2017	n/m a value too high to mean anything
2016	356×	230×	356×
2015	336×	333×	471×

Against its peers

Companies in Medical - Devices nearest DexCom's size, closest first, today.

Company	Price to free cash flow
DXCMDexCom	20.9×
GEHCGE HealthCare Technologies	20.4×
ZBHZimmer Biomet	12.3×
EWEdwards Lifesciences	35.8×
BSXBoston Scientific	18.3×
SYKStryker	25.1×
MDTMedtronic	19.9×
ABTAbbott Laboratories	n/m
LIVNLivaNova	30.1×
ITGRInteger	38.4×
Peer median	22.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on DexCom

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.